Understanding RSV and Why It’s a Threat to Seniors

respiratory Syncytial Virus (RSV) is frequently enough dismissed as a childhood illness, causing common cold-like symptoms. However,for older adults,RSV can be a serious threat,leading to pneumonia,bronchitis,hospitalization,and even death. Before the development of this vaccine, an estimated 60,000-160,000 older adults in the U.S. were hospitalized each year due to RSV, and 6,000-10,000 died.The virus weakens the respiratory system, making individuals more susceptible to secondary infections.

The impact of RSV on older adults is often underestimated. Symptoms can mimic those of influenza or COVID-19,leading to delayed diagnosis and treatment. Furthermore, the long-term effects of RSV infection can include a decline in physical function and an increased risk of chronic respiratory conditions.

The Arexvy Vaccine: How it Works and Clinical trial Results

Arexvy, developed by GSK, is a recombinant subunit vaccine.It contains a stabilized prefusion F protein, which is a key component of the RSV virus used to trigger an immune response. Unlike customary vaccines that use a weakened or inactivated virus, Arexvy doesn’t carry the risk of causing RSV infection.

The pivotal clinical trial, involving nearly 25,000 adults aged 60 years and older, demonstrated a notable efficacy against RSV-associated lower respiratory tract disease (LRTD). Specifically, the vaccine showed an overall efficacy of 82.6% in preventing LRTD, as detailed in the New England Journal of Medicine (September 25, 2025). Subgroup analysis revealed especially strong protection in those with underlying health conditions, such as chronic obstructive pulmonary disease (COPD) and heart failure.

Data published on September 25, 2025, in the New England Journal of Medicine also showed the vaccine’s efficacy remained consistent across different RSV subtypes and over a period of at least one year following vaccination.The most common side effects reported in the clinical trials were local reactions at the injection site, such as pain, redness, and swelling, and systemic symptoms like fatigue and muscle aches. Serious adverse events were rare and not definitively linked to the vaccine.

Who Should get the RSV Vaccine?

the CDC recommends that adults aged 60 years and older may receive a single dose of RSV vaccine, based on shared clinical decision-making